Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation

Exclusion Criteria

• •Patient has \>= grade 2 peripheral neuropathy within 14 days before enrollment and at D60-180 after AHCT; patients who had \>= grade 2 peripheral neuropathy within 14 days before enrollment but resolves to grade 1 or lower peripheral neuropathy at D60-D180 after AHCT can be enrolled at this time
• •Patient has \> 1.5 x upper limit of normal (ULN) total bilirubin unless history of Gilbert's syndrome
• •Myocardial infarction within 6 months prior to enrollment or has New York Heart Association (NYHA) class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities; prior to study entry, any electrocardiographic (ECG) abnormality at screening has to be documented by the investigator as not medically relevant
• •Patient has hypersensitivity to bortezomib, boron or mannitol
• •Female subject is pregnant or breast-feeding; confirmation that the subject is not pregnant must be established by a negative serum beta-human chorionic gonadotropin (beta-hCG) pregnancy test result obtained during screening; pregnancy testing is not required for post-menopausal or surgically sterilized women
• •Patient has received other investigational drugs with 14 days before treatment of treatment with bortezomib + rituximab
• •Serious medical or psychiatric illness likely to interfere with participation in this clinical study
• •Diagnosed or treated for another malignancy within 3 years of enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy
• •Patients with other active malignancies (no evidence of other cancer or life expectancy greater than 5 years) are ineligible for this study
• •Human immunodeficiency virus (HIV) positive patients or hepatitis B or C positive patients
• •Patients with active central nervous system (CNS) disease or history of brain metastases (mets) are excluded from study